Known targets — ChEMBL curated mechanism
EGFRERBB2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9
The experimentally established mechanism targets of Cudc-101. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 known ✓ | O15379 | 14/20 | 1.00 |
| ▸ | HDAC4 known ✓ | P56524 | 14/20 | 1.00 |
| ▸ | HDAC1 known ✓ | Q13547 | 14/20 | 1.00 |
| ▸ | HDAC7 known ✓ | Q8WUI4 | 14/20 | 1.00 |
| ▸ | HDAC2 known ✓ | Q92769 | 14/20 | 1.00 |
| ▸ | HDAC10 known ✓ | Q969S8 | 14/20 | 1.00 |
| ▸ | HDAC11 known ✓ | Q96DB2 | 14/20 | 1.00 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 14/20 | 1.00 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 14/20 | 1.00 |
| ▸ | HDAC9 known ✓ | Q9UKV0 | 14/20 | 1.00 |
| ▸ | HDAC5 known ✓ | Q9UQL6 | 14/20 | 1.00 |
| ▸ | ERBB2 known ✓ | P04626 | 8/20 | 1.00 |
| ▸ | EGFR known ✓ | P00533 | 8/20 | 1.00 |
| ▸ | KDR | P35968 | 7/20 | 1.00 |
| ▸ | GAK | O14976 | 1/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 1/20 | 1.00 |
| ▸ | BUB1 | O43683 | 1/20 | 1.00 |
| ▸ | STK10 | O94804 | 1/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 1.00 |
| ▸ | LCK | P06239 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cudc-101 SCHEMBL93769 | 1.00 | HDAC3 (1.00) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL8212688 | 1.00 | HDAC3 (1.00) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL4740600 | 1.00 | HDAC3 (1.00) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL641667 | 1.00 | HDAC3 (1.00) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| Cudc-101 SCHEMBL29350202 | 1.00 | HDAC3 (1.00) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL31424948 | 0.99 | HDAC3 (1.00) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL8213005 | 0.99 | HDAC3 (1.00) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL643712 | 0.99 | HDAC3 (1.00) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL642322 | 0.97 | HDAC3 (1.00) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL8205021 | 0.94 | ERBB2 (1.00) | HDAC3HDAC4HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022031952-A9 | TREATMENTS FOR CANCERS HAVING KRAS MUTATIONS | CITY OF HOPE (US) | 2022-04-07 | — | — | WO | claimed |
| WO-2022031952-A2 | TREATMENTS FOR CANCERS HAVING KRAS MUTATIONS | CITY OF HOPE (US) | 2022-02-10 | — | — | WO | claimed |
| WO-2025261943-A1 | ANTI-CANCER COMBINATIONS COMPRISING MOSPERAFENIB AND FOLFOX OR FOLFIRI | F. HOFFMANN-LA ROCHE AG (CH) | 2025-12-26 | — | — | WO | disclosed |
| US-20250381202-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | ZOUNEK ALEX (DE) | 2025-12-18 | — | — | US | disclosed |
| US-20250367145-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF KIDNEY DISEASES | UNIVERSITÄTSMEDIZIN GREIFSWALD (DE) | 2025-12-04 | — | — | US | disclosed |
| EP-4634172-A1 | COMBINATION THERAPY FOR CANCER TREATMENT | F. Hoffmann-La Roche AG (CH) | 2025-10-22 | — | — | EP | disclosed |
| US-12343428-B2 | Compositions and methods for cancer treatment | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2025-07-01 | — | — | US | disclosed |
| EP-4539835-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF KIDNEY DISEASES | Universitätsmedizin Greifswald (DE) | 2025-04-23 | — | — | EP | disclosed |
| EP-4444288-A1 | USE OF AN RXR AGONIST IN TREATING DRUG RESISTANT HER2+ CANCERS | Io Therapeutics, Inc. (US) | 2024-10-16 | — | — | EP | disclosed |
| EP-4426305-A1 | NOVEL USE OF QUINAZOLINONE COMPOUND FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2024-09-11 | — | — | EP | disclosed |
| US-20240293349-A1 | USE OF AN RXR AGONIST IN TREATING DRUG RESISTANT HER2+ CANCERS | Io Therapeutics, Inc. | 2024-09-05 | — | — | US | disclosed |
| US-20220211652-A1 | USE OF AN RXR AGONIST IN TREATING HER2+ CANCERS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2022-07-07 | — | — | US | disclosed |
| US-20220192984-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING OTIC THERAPEUTIC AGENTS AND RELATED METHODS | Frequency Therapeutics, Inc. | 2022-06-23 | — | — | US | disclosed |
| US-20220175776-A1 | COMBINATION OF CHIR99021 AND VALPROIC ACID FOR TREATING HEARING LOSS | Frequency Therapeutics, Inc. (US) | 2022-06-09 | — | — | US | disclosed |
| US-20220160664-A1 | TAZ ACTIVATORS AND WNT AGONISTS FOR TREATING EAR DISORDERS | UNITED STATES GOVERNMENT | 2022-05-26 | — | — | US | disclosed |
| EP-3990437-A1 | QUINAZOLIN-4-ONE DERIVATIVES USEFUL FOR THE TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS | Array Biopharma, Inc. (US) | 2022-05-04 | — | — | EP | disclosed |
| US-20220127568-A1 | COMPOSITIONS AND METHODS FOR GENERATING HAIR CELLS BY INHIBITING EPIGENETIC TARGETS | Frequency Therapeutics, Inc. (US) | 2022-04-28 | — | — | US | disclosed |
| WO-2022031952-A9 | TREATMENTS FOR CANCERS HAVING KRAS MUTATIONS | CITY OF HOPE (US) | 2022-04-07 | — | — | WO | disclosed |
| US-11260130-B2 | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV | Frequency Therapeutics, Inc. (US) | 2022-03-01 | — | — | US | disclosed |
| WO-2022031952-A2 | TREATMENTS FOR CANCERS HAVING KRAS MUTATIONS | CITY OF HOPE (US) | 2022-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127568-A1 | COMPOSITIONS AND METHODS FOR GENERATING HAIR CELLS BY INHIBITING EPIGENETIC TARGETS | WNT3A, WNT1, MECP2 | HDAC3 397/4885HDAC4 197/4885HDAC1 91/4885 |
| US-20250381202-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | KIT, CTSL, PAICS | HDAC3 1207/4885HDAC4 2349/4885HDAC1 517/4885 |
| US-20240293349-A1 | USE OF AN RXR AGONIST IN TREATING DRUG RESISTANT HER2+ CANCERS | ERBB2, RXRG, THRA | HDAC3 521/4885HDAC4 438/4885HDAC1 1457/4885 |
| US-20220175776-A1 | COMBINATION OF CHIR99021 AND VALPROIC ACID FOR TREATING HEARING LOSS | HES1, SHH, HDAC11 | HDAC3 74/4885HDAC4 53/4885HDAC1 9/4885 |
| US-20250367145-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF KIDNEY DISEASES | REN, SLC10A1, GLS | HDAC3 573/4885HDAC4 1252/4885HDAC1 1068/4885 |
| US-20220211652-A1 | USE OF AN RXR AGONIST IN TREATING HER2+ CANCERS | ERBB2, THRA, RXRA | HDAC3 654/4885HDAC4 426/4885HDAC1 1505/4885 |
| US-20220160664-A1 | TAZ ACTIVATORS AND WNT AGONISTS FOR TREATING EAR DISORDERS | WNT1, WNT3A, CTNNB1 | HDAC3 4107/4885HDAC4 2918/4885HDAC1 3440/4885 |
| US-20220192984-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING OTIC THERAPEUTIC AGENTS AND RELATED METHODS | OTC, EXOSC5, ENTPD5 | HDAC3 4069/4885HDAC4 3999/4885HDAC1 3253/4885 |
| US-11260130-B2 | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV | GSK3B, GSK3A, GSKIP | HDAC3 1194/4885HDAC4 704/4885HDAC1 804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.